Lyophilized Formulations of Exendins and Exendin Agonist Analogs
First Claim
Patent Images
1. A lyophilized formulation comprising about 0.005% (w/v) to about 0.4% (w/v) exendin-4 and about 1.0% (w/v) to about 10% (w/v) mannitol.
3 Assignments
0 Petitions
Accused Products
Abstract
Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.
-
Citations
20 Claims
-
1. A lyophilized formulation comprising about 0.005% (w/v) to about 0.4% (w/v) exendin-4 and about 1.0% (w/v) to about 10% (w/v) mannitol.
- 2. A lyophilized formulation comprising about 0.005% (w/v) to about 0.4% (w/v) of an exendin or an exendin agonist analog and about 1.0% (w/v) to about 10% (w/v) of mannose, ribose, trehalose, maltose, glycerol, inositol, glucose, lactose, galactose, arabinose, sorbitol, mannitol, glycerol, xylitol, a polypropylene/ethylene glycol copolymer, a polyethylene glycol, or a combination thereof.
- 5. A lyophilized formulation comprising about 0.005% (w/v) to about 0.4% (w/v) of an exendin or an exendin agonist analog and about 1.0% (w/v) to about 10% (w/v) of a bulking agent.
Specification